Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01675973 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine
A Phase 1 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT01675973 is a Phase 1 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 4 participants.
The verdict
NCT01675973, a Phase 1 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect of severe renal impairment on the steady-state PK, as well as safety and tolerability, of ranolazine, compared to subjects with normal renal function.
Interventions
- DRUG RANEXA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2012-07 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01675973
The ClinicalTrials.gov registry entry for NCT01675973 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RANEXA is the first listed.
NCT01675973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01675973 about?
NCT01675973 is a clinical study titled "A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine". The purpose of this study is to assess the effect of severe renal impairment on the steady-state PK, as well as safety and tolerability, of ranolazine, compared to subjects with normal renal function.
What is the current status of trial NCT01675973?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2012-07. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01675973?
The interventions under investigation include: RANEXA (DRUG).
Who is sponsoring clinical trial NCT01675973?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.